About the Sickle Cell Disease Treatment Demonstration Program (SCDTDP)

In 2004 Congress enacted and the President signed into law P.L 108-357, the American Jobs Creation Act of 2004. Section 712 of P.L. 108-357 which authorized a demonstration program for the prevention and treatment of sickle cell disease.

The legislation was to address "inclusion of primary and secondary medical strategies for children and adults with sickle cell disease as medical assistance under the Medicaid program" and was enacted for two purposes:

  • the creation of an optional medical assistance program for individuals with sickle cell diseases for treatment and education, genetic counseling and other services to prevent mortality and decrease morbidity from sickle cell disease; and
  • the creation of a demonstration program, the SCDTP including a National Coordinating Center, (SCDNCC) under Health Resources and Services Administration (HRSA) http://mchb.hrsa.gov/

The SCDTP is designed to improve and expand patient and provider education and the continuity and coordination of service delivery for individuals with sickle cell disease through grants to eligible entities. It aims to improve access to services for individuals with sickle disease by providing an opportunity for Federally Qualified Health Centers (FGHCs) FQHC Look-Alikes, and other primary care clinics to partner with comprehensive sickle cell disease centers and community-based sickle cell disease organizations to deliver high quality clinical care.

R. Lorraine Brown, the HRSA Project Officer for the SCDTP can be contacted at:
lbrown@hrsa.gov
301-443-9775